Neuphoria Therapeutics (NEUP) Financials

Neuphoria Therapeutics (NASDAQ: NEUP) remains a development-stage biotech with no meaningful product revenue in the latest quarter, and its financial picture is still defined by operating losses, cash usage, and a large amount of balance-sheet goodwill/intangibles from prior transactions.

For Q3 2026, the company reported no revenue and a net loss of $505 thousand, or -$0.09 per share. That is a much smaller loss than the $8.9 million net loss in Q4 2025, but the comparison is not apples-to-apples because the share count changed dramatically across periods. Operating expenses in Q3 2026 were $1.2 million, with SG&A at $1.7 million and R&D showing a negative reported value in the data, while other income helped offset the operating loss.

The biggest positive change in the latest quarter was the balance sheet. Neuphoria ended Q3 2026 with $19.4 million in cash and equivalents, up from $17.0 million in Q3 2025. Total assets were $34.8 million versus $30.7 million a year earlier, while total liabilities were relatively modest at $5.4 million. That gives the company a strong near-term liquidity position, at least on a balance-sheet basis.

Still, investors should note that the company continues to carry a meaningful amount of goodwill ($8.8 million) and intangible assets ($4.3 million), which together represent a large portion of total assets. Retained earnings remain deeply negative at -$186.9 million, reflecting years of cumulative losses.

Looking at the broader trend over the last four years, NEUP’s income statement has been highly volatile. The company has repeatedly posted no revenue or very limited revenue in most quarters, while expenses have remained significant. In some periods, especially in 2025, there were unusually large swings in “other income/expense” and share count, which can make per-share results and quarterly comparisons difficult to interpret.

Cash flow also shows the company depends heavily on financing to support operations. In the latest reported Q4 2025 cash flow statement, operating cash flow was negative $3.6 million, and financing provided only $704 thousand. In prior quarters, cash was often supported by equity issuances, including very large raises in 2024 and 2025. That suggests the company has historically funded its operations by tapping capital markets rather than generating operating cash flow.

• Cash position improved: Cash and equivalents rose to $19.4 million in Q3 2026 from $17.0 million a year earlier.
• Liabilities remain manageable: Total liabilities of $5.4 million are low relative to total assets.
• Latest quarter loss narrowed sharply: Q3 2026 net loss of $505 thousand was far smaller than losses seen in several prior quarters.
• Large non-operating assets remain on the books: Goodwill and intangible assets still make up a meaningful share of assets.
• Operating results remain difficult to compare: Share count and “other income/expense” have been very volatile quarter to quarter.
• Balance sheet shows accumulated losses: Retained earnings are still deeply negative at -$186.9 million.
• No consistent revenue base: The company reported no revenue in Q3 2026 and several other periods.
• Ongoing dependence on external funding: Cash flow history shows repeated reliance on equity financing to support operations.
• Operating cash flow has been negative: Q4 2025 operating cash flow was -$3.6 million.
• Biotech risk remains high: Until the company develops a durable revenue stream, results will likely stay uneven and financing-dependent.

Bottom line: Neuphoria Therapeutics currently looks like a cash-rich but still highly speculative biotech. The company’s liquidity is better than its headline losses might suggest, but the absence of stable revenue and the ongoing need for financing remain the key risks for retail investors.